ESMO Sarcoma and Rare Cancers 2023 | The role of P53 in the early detection of sarcoma

David Thomas, PhD, FRACP, The Kinghorn Cancer Centre, Sydney, Australia, discusses how whole genome sequencing can be utilized to identify p53 mutations that drive the progression of silent sarcomas at early disease stages. Prof. Thomas emphasizes the significance of whole-body MRI in detecting these silent malignancies at a curable stage, whilst also highlighting the prospect of potential blood-based detection strategies to enhance detection and intervention in those at risk. This interview took place at the 2023 ESMO annual Sarcoma and Rare Cancers congress in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.